Edited by Paul E. Fraser ␣-Synuclein (␣syn) aggregates into toxic fibrils in multiple neurodegenerative diseases where these fibrils form characteristic pathological inclusions such as Lewy bodies (LBs). The mechanisms initiating ␣syn aggregation into fibrils are unclear, but ubiquitous post-translational modifications of ␣syn present in LBs may play a role. Specific C-terminally (C)-truncated forms of ␣syn are present within human pathological inclusions and form under physiological conditions likely in lysosome-associated pathways, but the roles for these C-truncated forms of ␣syn in inclusion formation and disease are not well understood. Herein, we characterized the in vitro aggregation properties, amyloid fibril structures, and ability to induce full-length (FL) ␣syn aggregation through prion-like mechanisms for eight of the most common physiological C-truncated forms of ␣syn (1-115, 1-119, 1-122, 1-124, 1-125, 1-129, 1-133, and  1-135) . In vitro, C-truncated ␣syn aggregated more readily than FL ␣syn and formed fibrils with unique morphologies. The presence of C-truncated ␣syn potentiated aggregation of FL ␣syn in vitro through co-polymerization. Specific C-truncated forms of ␣syn in cells also exacerbated seeded aggregation of ␣syn. Furthermore, in primary neuronal cultures, co-polymers of C-truncated and FL ␣syn were potent prion-like seeds, but polymers composed solely of the C-truncated protein were not. These experiments indicated that specific physiological C-truncated forms of ␣syn have distinct aggregation properties, including the ability to modulate the prion-like aggregation and seeding activity of FL ␣syn. Proteolytic formation of these C-truncated species may have an important role in both the initiation of ␣syn pathological inclusions and further progression of disease with strain-like properties.
␣-Synuclein (␣syn) aggregates into toxic fibrils in multiple neurodegenerative diseases where these fibrils form characteristic pathological inclusions such as Lewy bodies (LBs). The mechanisms initiating ␣syn aggregation into fibrils are unclear, but ubiquitous post-translational modifications of ␣syn present in LBs may play a role. Specific C-terminally (C)-truncated forms of ␣syn are present within human pathological inclusions and form under physiological conditions likely in lysosome-associated pathways, but the roles for these C-truncated forms of ␣syn in inclusion formation and disease are not well understood. Herein, we characterized the in vitro aggregation properties, amyloid fibril structures, and ability to induce full-length (FL) ␣syn aggregation through prion-like mechanisms for eight of the most common physiological C-truncated forms of ␣syn (1-115, 1-119, 1-122, 1-124, 1-125, 1-129, 1-133, and 1-135). In vitro, C-truncated ␣syn aggregated more readily than FL ␣syn and formed fibrils with unique morphologies. The presence of C-truncated ␣syn potentiated aggregation of FL ␣syn in vitro through co-polymerization. Specific C-truncated forms of ␣syn in cells also exacerbated seeded aggregation of ␣syn. Furthermore, in primary neuronal cultures, co-polymers of C-truncated and FL ␣syn were potent prion-like seeds, but polymers composed solely of the C-truncated protein were not. These experiments indicated that specific physiological C-truncated forms of ␣syn have distinct aggregation properties, including the ability to modulate the prion-like aggregation and seeding activity of FL ␣syn. Proteolytic formation of these C-truncated species may have an important role in both the initiation of ␣syn pathological inclusions and further progression of disease with strain-like properties.
Lewy body dementia (LBD)
2 and Parkinson's disease (PD) are pathologically characterized by neuronal Lewy body (LB) inclusions composed of amyloidogenic ␣-synuclein (␣syn), along with associated gliosis and neurodegeneration (1) (2) (3) (4) . The propensity of ␣syn to aggregate into ␤-sheet-rich fibrils has been posited to play a crucial role in the initiation and progression of disease, as a number of familial ␣syn missense mutants that cause hereditary PD/LBD accelerate this aggregation process (5) (6) (7) (8) (9) . Furthermore, these aggregation-prone ␣syn mutants have been successfully utilized to generate robust murine models of disease (10, 11) . The resulting ␣syn fibrils found in LB inclusions have the capacity to recruit endogenous ␣syn into further fibrils through a prion-like process termed conformational templating (2, 12) ; this property of fibrillar ␣syn in combination with its observed toxicity and ability to spread intercellularly suggests that ␣syn fibrils may underlie disease pathogenesis (13) (14) (15) (16) .
The importance of ␣syn fibrils to disease progression has been established; however, mechanisms by which initial fibrils form are not well-understood. In the absence of pre-existing fibrils to catalyze ␣syn aggregation, initial fibrils are posited to slowly assemble from monomeric ␣syn (17) (18) (19) . This aggregation process can be promoted by toxic cellular insults, notably those that impair lysosomal chaperone-mediated autophagy, which is the major clearance pathway for physiologic and fibrillar ␣syn (20 -23) . Specifically, impaired lysosomal function as is seen in risk factors for PD, including glucocerebrosidase insufficiency, lysosomal storage diseases, or aging in general, may promote such toxic aggregation (24 -29) . In particular, lysosomal impairment may promote formation of C-terminally truncated ␣syn through incomplete lysosomal proteolytic digestion, which has been demonstrated in vitro and in cell culture (22, 30 -34) . C-terminal truncation of ␣syn has been repeatedly shown to promote in vitro fibril formation more promptly than even ␣syn harboring the familial A53T mutation or any other post-translational modification (35) (36) (37) (38) (39) (40) (41) . Indeed, monomers of C-truncated ␣syn will self-assemble into fibrils resembling those found in LBs with minimal incubation; comparatively, full-length (FL) ␣syn requires days of continual incubation along with vigorous shaking to form characteristic fibrils (36, 37) . Unlike rare familial disease-causing mutant forms of ␣syn, C-truncated species are presumably found in all neurons, as ubiquitous lysosomal proteases are implicated in their formation (22, 30 -34) .
Immunodetection of pathologic ␣syn from patient samples reveals the striking role C-truncated ␣syn may have in the pathophysiology of PD and LBD. Brain lysate from PD and LBD patients demonstrates an abundance of C-truncated ␣syn in the detergent-insoluble, aggregated fractions compared with controls; truncated ␣syn is estimated to represent 10 -25% of total ␣syn within these LB extracts (42) (43) (44) (45) (46) . Furthermore, truncation-specific antibodies have been used to localize C-truncated ␣syn to the center of LBs where FL ␣syn occupies a more circumferential location, suggesting an initiating role for C-truncated ␣syn in the generative processes of these inclusions (47, 48) .
Truncated forms of ␣syn are elevated in PD and LBD, but only limited studies have gone beyond this association and explored mechanistic implications for disease. Overexpression of some C-truncated forms of ␣syn in cell culture, in Drosophila, and in murine models mainly under the rat TH promoter has demonstrated that these truncations tend to be more toxic than the FL protein, and the mouse models have displayed motor symptoms, filamentous neuronal inclusion formations, and dopaminergic dysfunction (34, 43, 49 -57) . The mitochondrial toxicity of these truncated species may also be critically important in mediating cellular demise (58) . As useful as these studies have been, many of these models have used truncations not commonly found in human disease or have examined the truncations in the absence of FL human ␣syn. Herein, a full panel of the C-terminally truncated ␣syn proteins confirmed to exist in LBs and form in human cells (32, 45, 46) are examined in cultured cells for their propensity to aggregate and do so synergistically with FL ␣syn. Additionally, the ability of preformed C-truncated ␣syn fibrils to further ␣syn aggregation in neuronal-glial culture is also studied.
Results

Physiologic C-truncation of ␣syn readily promotes aggregation in vitro
To investigate differences in aggregate formation kinetics in vitro between human FL ␣syn and the eight major C-truncated ␣syn species that form under physiologic conditions (Fig. 1) , monomers of each were diluted to 150 M in PBS and incubated at 37°C with shaking over the course of 96 h. The rate of ␣syn amyloid formation was monitored using fluorometry, as ␣syn fibrils are amyloidogenic (59) , and their formation can be quantified using the fluorescent amyloid binding dyes K114 and thioflavin T (ThT) (59, 60) . K114 is derived from the structure of Congo Red and binds a different amyloid site than ThT (60) . Fluorometry readings were normalized to the fraction of insoluble protein at the final 96-h time point (Fig. S1, A and B) . Serial fluorometric readings with both ThT and K114 (Fig. 2 , B and C) revealed a sigmoidal transition from soluble monomers to insoluble fibrils for all C-truncated forms of ␣syn, which is characteristic of in vitro amyloid formation processes (17) . The 1-115, 1-119, and 1-125 ␣syn truncations showed substantially increased aggregation rates compared with FL ␣syn using ThT, which is evidenced by their left-shifted sigmoidal curves. At just 6 h of incubation, these three truncations had attained ϳ50% or more of their eventual peak ThT fluorescence, whereas comparatively, the FL ␣syn did not reach this level until at least 48 h. The 1-122, 1-124, and 1-129 ␣syn truncations fibrillized more readily than FL ␣syn, as evidenced by significantly increased normalized ThT fluorescence at 24 h (Table 1) ; however, the effect was less compared with the 1-115, 1-119, and 1-125 ␣syn truncations. Last, the 1-133 ␣syn and 1-135 ␣syn demonstrated no significant difference in aggregation measured by fluorometry compared with FL ␣syn at any time point (Table 1) . In addition to the rate of formation, the total extent of aggregation for each C-truncated form of ␣syn was assessed using centrifugal sedimentation analysis at Figure 1 . Depiction of the structural domains of ␣syn and the sites of physiologic C-terminal truncation used in this study. Shown is a layout of the three principle regions of the FL 1-140 isoform of human ␣syn. The amphipathic N terminus harbors a number of imperfect repeats important in generating helical structure for membrane interactions; the locations of all familial disease-causing mutations are in this region and shown in red. The hydrophobic NAC region is crucial in generating the core of fibrils and is thought to mediate prion-like conformational templating. The acidic C terminus contains two negatively charged repeats; its 15 negatively charged residues, 5 prolines, and long-range interactions with the NAC to shield it from pathologic aggregation all act as inhibitors of fibril formation. C-terminal truncations found to occur in human cells, isolated from LBs, and used in this study are indicated by arrows and numbered at the cleaved residue.
Pathologic C-terminal truncation of ␣-synuclein the last time point. At 96 h of incubation, ␣syn truncations 1-129 and shorter had a modest increase in aggregation extent compared with FL ␣syn (Fig. S1, A and B) , where 77.8 Ϯ 2.8% of FL ␣syn had become insoluble in PBS compared with 99.0 Ϯ 0.9% for the 1-115 ␣syn. Comparatively, 1-133 and 1-135 ␣syn showed only a slight increase in the final amount of insoluble ␣syn as determined from sedimentation analysis. These results demonstrate that in vitro, physiologic C-terminally truncated forms of ␣syn aggregate more extensively and at a faster rate compared with FL ␣syn, and the effect is generally accentuated with the increased extent of C-terminal truncation.
C-truncated ␣syn forms amyloid fibrils assessed by transmission EM
FL ␣syn is known to assemble in vitro into amyloid fibrils ranging between 5 and 12 nm in width (7, 37, (61) (62) (63) . To assess whether physiologic C-truncated ␣syn forms similar fibrils, FL and C-truncated ␣syn proteins were individually incubated with shaking for 5 days followed by negative staining EM. All forms of C-truncated ␣syn displayed fibril formation with a characteristic straight, unbranched appearance similar to FL ␣syn (Fig. 3) . Notably, fibrils composed of certain shorter C-truncations, such as 1-115, 1-119, 1-122, and 1-125 ␣syn, tended to be shorter in length compared with those from FL ␣syn, consistent with previous reports for other C-truncations (35, 37, 38) . Additionally, the fibrils composed of the shorter proteins often formed dense "clumps" on the EM grid as opposed to a more even disbursement of fibrils, as is the case with fibrils composed of FL ␣syn; this clustering is likely the result of less C-terminal charge, which otherwise would impair lateral packing of fibrils and has been reported for other C-truncations (35, (37) (38) (39) (Fig. 3 ). This analysis demonstrates that all C-truncated forms of ␣syn formed physiologically and commonly detected in LBs are capable of assembling into typical amyloid fibrils, albeit some with morphologic differences from FL ␣syn.
C-truncated ␣syn forms amyloid fibrils with differing proteolytic digestion profiles
Differential digestion products upon exposure to the proteases trypsin or proteinase K have been used previously to characterize differing strains of ␣syn, as alternative fibril structures appear to undergo unique patterns of proteolytic digestion (64, 65) . To ascertain unique digestion product profiles for each C-truncated form of ␣syn, fibrils were assembled from each and incubated with two different concentrations of trypsin or proteinase K, followed by SDS-PAGE analysis (Fig. S2) . Indeed, for trypsin and proteinase K digestion, resulting species varied in both size and number between the different C-truncated fibrils (Fig. S2 ). For C-truncations 1-125 and shorter, trypsin digestion results in two predominant bands, whereas three or more are evident for 1-129 and longer. For proteinase K digestion, only two major bands are seen for the 1-115, 1-122, and 1-124 fibrils, whereas multiple bands are evident for the others. This experiment indicates that structural differences may exist between these fibrils. Aggregation propensities between different ␣syn missense mutants and other amyloid-forming proteins such as tau have been successfully studied in a cell culture model utilizing HEK293T cells, whereby cells are induced to express ␣syn through calcium phosphate transfection, preformed ␣syn fibrils are added, and resulting aggregation is assessed using detergent extraction, where monomeric, soluble and aggregated, insoluble ␣syn are quantified via Western blotting (66 -68) . Using the same model with a similar experimental paradigm, our eight C-truncated forms of ␣syn (Fig. 1) were expressed in HEK293T cells with or without treatment of preformed fibrils composed of 1 M 21-140 ␣syn, and the results were compared with cells expressing FL ␣syn with the same treatment. The 21-140 ␣syn fibrils induce pathology similarly to FL ␣syn fibrils but are not detected by N-terminal antibody SNL4 (residues 2-12 in ␣syn), allowing for detection of only expressed ␣syn (66, 69 -72) . Cells were harvested in Triton X-100 fractionation buffer and the insoluble fibrillar species were isolated from soluble ␣syn by ultracentrifugation. Without the addition of fibrillar ␣syn seeds, intrinsically detergentinsoluble species were not observed for any of the C-truncated forms of ␣syn investigated (Fig. 4C) . Treatment with ␣syn fibrillar seeds induced intracellular ␣syn aggregation for FL ␣syn and all eight C-truncated forms of ␣syn (Fig. 4A) . Compared with FL ␣syn, 1-129 and shorter C-truncated forms of ␣syn aggregated to a much greater extent (Fig. 4, A and B) , whereas the truncations most like FL (1-133 and 1-135 ␣syn) aggregated similarly to FL ␣syn. A biphasic trend is also discernible, whereby truncation accelerates aggregation up until 1-124 ␣syn, which corresponds to complete removal of the second acidic repeat in the C terminus of ␣syn (Fig. 1) ; this trend of truncation increasing aggregation repeats itself from 1-124 to 1-115. Of note, a doublet band was observed in the insoluble portion for the 1-119 ␣syn; it is unclear whether this is due to additional truncation or an alternative stable conformer. Overall, these findings demonstrate that the enhanced aggregation propensity of C-terminally truncated ␣syn observed in vitro can be extended to a cellular milieu.
The seeded aggregation of these C-truncated forms of ␣syn was further studied by utilizing immunofluorescence to directly visualize inclusions formed in HEK293T cells expressing C-truncated ␣syn and treated with 21-140 ␣syn fibrils, which are not detected by the antibodies used. SNL4 staining was ubiquitous for each truncation, suggesting similar levels of expression between them (Fig. 5) . Additionally, SNL4 staining was seen throughout the cell body and processes, indicating that monomeric forms of ␣syn were detected. Syn 506 is an antibody that preferentially detects aggregated ␣syn in cultured cells (73) , and Syn 506 detection was limited largely to rounded inclusions for all of the seeded cells but was minimal in unseeded cells (Fig. 5 ). In these experiments, more cells harbored Syn 506 -positive inclusions when expressing C-truncated forms of ␣syn that aggregated more extensively in biochemical studies, notably those 1-129 and shorter. Morphologically, inclusions were similar in size and shape between the different truncations. These findings suggest that the increased amount of seeded aggregation found for shorter C-truncated forms of ␣syn is due to a higher probability of aggregation occurring in a given cell, leading to a higher number of Syn 506 -positive cells.
The presence of C-truncated ␣syn enhances aggregation of FL ␣syn in vitro
Previous in vitro experiments have reported an enhancement of FL ␣syn aggregation when co-fibrillized with some C-truncated ␣syn monomers (35, 42, 43) . To further assess this phenomenon using some of the distinct physiologic C-truncations, Pathologic C-terminal truncation of ␣-synuclein either 1-115, 1-125, 1-129, or 1-135 ␣syn was diluted to 25 M in PBS, and FL ␣syn was additionally added to 25 M (n ϭ 4). Aggregation was then induced with shaking at 1050 rpm, 37°C, and soluble versus insoluble FL ␣syn was compared at time points of 0, 12, 24, 48, and 96 h using sedimentation analysis and densitometry ( Fig. 6 and Table 2 ). For the 1-135/FL ␣syn mixture, little if any aggregation occurred, as the 1-135 ␣syn truncation appears to be highly similar to the FL protein, which does not appreciably aggregate at this concentration. Comparatively, with increasing extent of C-truncation from 1-129 and shorter, the FL protein is induced to aggregate at earlier time points. Most striking was the mixture of 1-115 with FL ␣syn, where within 12 h, FL ␣syn had aggregated to a greater extent than FL ␣syn alone at 150 M and 96 h (Fig. S1, A and B) . Furthermore, FL ␣syn and C-truncations appear to co-polymerize, as these became insoluble in a 1:1 ratio. These results demonstrate that physiologically C-truncated forms of ␣syn can directly accelerate formation of FL ␣syn fibrils through their robust tendency to aggregate.
Aggregation of FL ␣syn is enhanced by the presence of C-truncated ␣syn through the formation of mixed fibrils as visualized using immuno-EM
The results of the previous experiment were further investigated utilizing immuno-EM to determine the mechanism by which C-truncated ␣syn was enhancing aggregation of FL ␣syn. 21-140 and either 1-115 or 1-129 ␣syn were co-aggregated in a 1:1 ratio to form fibrils that were immunolabeled with antibodies 4110 (residues 2-15 in ␣syn) and 94-3A10 (residues 130 -140 in ␣syn). Control fibrils composed entirely of 21-140, 1-129, or FL ␣syn at the same concentration as the co-aggregated fibrils were immunolabeled as well to demonstrate epitope specificity. Fibrils composed of either 21-140 ϩ 1-115 ␣syn or 21-140 ϩ 1-129 ␣syn were labeled with both antibodies 4110 and 94-3A10 when visualized using EM, demonstrating the presence of both the 21-140 ␣syn and C-truncated ␣syn within the same fibrils (Fig. 7B ). The two antibodies were often binding tar- A, Western blots detecting the amount of Triton X-100 -soluble and -insoluble ␣syn from each cell culture sample (n ϭ 3) that was transfected with the indicated ␣syn truncation and treated with 1 M 21-140 ␣syn fibrils. SNL4 against residues 2-12 of ␣syn was used, as it does not react with exogenous added fibrils. C-truncated ␣syn aggregates to a greater extent than FL ␣syn in this cellular model, and the effect is accentuated with increasing truncation. B, densitometric analysis of the blots in A; one-way ANOVA with Dunnett's test determined a large significant increase in the final extent of aggregation for C-terminal truncations 1-129 ␣syn and shorter. Error bars, S.D. ns, no significance; ****, p Յ 0.0001. C, Western blot analysis of Triton X-100 -soluble versus insoluble FL and C-truncated forms of ␣syn expressed in HEK293T cells with no added fibrils. Antibody SNL4 against residues 2-12 of ␣syn was used. No spontaneous aggregation was observed in this cell culture model. D, representative FL Western blotting (1-115 and 1-119 ␣syn) of SNL4 demonstrating specificity for ␣syn.
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gets within a few nanometers of each other on the same fibril, suggesting that the 21-140 and C-truncated forms of ␣syn are each present throughout the mixed fibrils. FL ␣syn fibrils were also detected by both antibodies, whereas 1-129 ␣syn fibrils were only labeled by antibody 4110, and 21-140 ␣syn fibrils were only detected by antibody 94-3A10. These findings indicate that aggregation-prone C-truncated forms of ␣syn can induce FL ␣syn to aggregate through the formation of mixed fibrils, as opposed to C-truncated ␣syn independently forming fibrils that later seed FL aggregation.
The presence of C-truncated forms of ␣syn enhances aggregation of FL ␣syn in cell culture
To probe for any synergistic interactions in the aggregation process between FL and C-truncated forms of ␣syn in cultured cells, HEK293T cells were co-transfected with plasmids expressing equal amounts of C-truncated and FL ␣syn, followed by the addition of preformed 21-140 ␣syn fibrils. Control transfections were performed where a pcDNA plasmid expressing FL ␣syn was co-transfected with the empty pcDNA plasmid or a double amount of pcDNA plasmid expressing FL ␣syn to examine whether a 2-fold alteration could significantly affect aggregation propensity, but similar levels of ␣syn were observed regardless (Fig. 8, A and B) . Co-expression of plasmids encoding 1-135 or 1-124 ␣syn did not significantly influence the aggregation of FL ␣syn (Fig. 8B) . For ␣syn C-truncations 1-133 and shorter, a trend 4) . B, densitometric analysis of the gels in A, quantifying the amount of FL ␣syn aggregation at each time point for each co-fibrillization; more extensive C-truncation leads to quicker FL ␣syn aggregation in a synergistic fashion. Error bars, S.D.
Table 2 Statistical summary of in vitro co-aggregation rates
The fraction of insoluble FL ␣syn (Fig. 5B ) for each C-truncated/FL ␣syn co-fibrillization reaction at each time point was compared with that of FL/1-135 ␣syn using two-way ANOVA and Dunnett's multiple-comparison test. The FL/1-115 co-fibrillization leads to almost complete aggregation of FL ␣syn within 12 h, whereas little to no aggregation is seen for the FL/1-135 co-fibrillization at any time point. NS, no significance; *, p Յ 0.05; **, p Յ 0.01; ****, p Յ 0.0001. 
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is observed whereby co-transfection for plasmids encoding increasingly C-truncated ␣syn leads to a greater proportion of aggregated, insoluble FL ␣syn (Fig. 8B) . Aggregation of FL ␣syn, where cells were transfected with plasmid encoding FL ␣syn ϩ empty plasmid or double the amount of FL ␣syn plasmid, was 30.0 Ϯ 3.8 and 29.9 Ϯ 0.4%, respectively. The amount of FL ␣syn aggregation was increased to 53.0 Ϯ 4.2 and 58.1 Ϯ 1.8% when co-transfected with plasmids encoding the 1-115 ␣syn and 1-119 ␣syn. This trend of a synergistic increase in FL aggregation with further C-terminal truncation is broken by the 1-124 ␣syn truncation, corresponding to the removal of one entire acidic C-terminal repeat (Fig. 1) . These results suggest that a pathologic role for C-truncated ␣syn may not just be limited to cellular dysfunction resulting from its own aggregation, but in fact ␣syn C-truncations that are primed to aggregate may assist in initiating FL ␣syn fibrillization. Furthermore, this synergistic aggregation is mechanistically explained by formation of fibrils containing both C-truncated and FL ␣syn, as evidenced by in vitro experiments and immuno-EM. Results of the previous experiments show that ␣syn fibrils form much more readily when both C-truncated and FL ␣syn are present compared with FL ␣syn alone. Furthermore, these fibrils contain both C-truncated and FL ␣syn when both are available in aggregation conditions. To determine the ability of these mixed C-truncated/FL ␣syn fibrils to seed FL ␣syn aggregation in cultured cells, the eight C-truncated forms of ␣syn ( Fig. 1) but further missing N-terminal residues 1-20 (to allow for detection of only the cellularly expressed ␣syn using antibody SNL4) were co-fibrillized with 21-140 ␣syn in a 1:1 ratio and added at 1 M to HEK293T cells transfected to express FL ␣syn (Fig. 9, A and B) . Control experiments were performed where 21-140 ␣syn fibrils alone were added at either 0.5 or 1 M for comparison (Fig. 9, A and B) . All of the mixed fibrils composed of FL and C-truncated forms of ␣syn were capable of inducing substantial but similar FL ␣syn aggregation compared with fibrils composed of only FL ␣syn. A small but significant decrease in aggregation is seen when only 21-140 ␣syn fibrils are used but at half the concentration, indicating that the presence of C-truncated ␣syn can substitute for FL ␣syn in the fibril structure while maintaining pathogenicity (Fig. 9B ). These findings demonstrate that mixed fibrils containing C-truncated and FL ␣syn fibrils that form at an accelerated rate are equally potent in their prion-like ability to propagate ␣syn aggregation compared with FL ␣syn fibrils.
Fibrils composed entirely of C-truncated ␣syn cross-seed FL ␣syn less efficiently in cell culture, suggesting structural incompatibility Recent evidence suggests that fibrils formed entirely of C-truncated ␣syn can be conformationally distinct (41) , as is the case with fibrils composed of E46K ␣syn or proposed alternative strains of ␣syn (74 -78); these alternative ␣syn fibrils often have inefficient cross-seeding of FL ␣syn, which is seen with added E46K fibrils to FL ␣syn (74, 79) . To investigate the ability of fibrils composed entirely of C-truncated forms of ␣syn to template polymerization of FL ␣syn, HEK293T cells were transfected with the plasmid expressing FL ␣syn and treated with 1 M preformed fibrils individually composed of each of the eight truncations used in this study or the 21-140 ␣syn control. The antibody 94-3A10 that requires residues 135-140 in ␣syn does not detect any C-truncations used and was used to detect FL ␣syn expressed in the cells (80) . Most of the fibrils composed solely of C-truncated forms of ␣syn seeded FL ␣syn less efficiently than 21-140 ␣syn, and 1-122 and 1-124 ␣syn fibrils induced little if any FL ␣syn aggregation (Fig. 10, A and  B) . These results indicate that fibrils composed entirely of C-truncated ␣syn are structurally distinct and consequently less efficient in seeding FL ␣syn, demonstrating that the C terminus of ␣syn has an active role in determining fibril structure.
The 5G9 mAb preferentially detects aggregated mouse ␣syn
To facilitate identification of aggregated mouse ␣syn in neuronal-glial culture, a novel mAb raised against residues 117-129 of mouse ␣syn was generated. Specificity for mouse ␣syn with no cross-reactivity for human ␣syn was demonstrated using both recombinant protein and HEK293T cell culture lysate, where cells were transfected to express either human or mouse ␣syn (Fig. S3A) . Furthermore, using tissue from C3HBL/6 mice intrastriatally injected with mouse ␣syn fibrils, which demonstrate ␣syn inclusions in the ipsilateral entorhinal cortex (81), the 5G9 antibody was shown to preferentially bind to aggregated mouse ␣syn, paralleling staining for pSer 129 (Fig.  S3B) . Additionally, there was no 5G9 staining in the contralateral entorhinal cortex, where pathology was not present in the mice used, demonstrating that this antibody is conformationally specific for mouse ␣syn in an aggregated state. This experiment provides a useful tool for detection of aggregated mouse ␣syn induced to form from human ␣syn fibrils. 
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Fibrils composed entirely of C-truncated human ␣syn seed mouse FL ␣syn inefficiently in neuronal-glial culture, suggesting structural incompatibility To confirm the observation that fibrils composed entirely of C-truncated ␣syn do not seed FL ␣syn efficiently, primary neuronal-glial cultures isolated from the cortex of embryonic day 16 (E16) C3HBL/6 mice were treated for 10 days with 1.5 M C-truncated fibrils composed entirely of either 1-115, 1-125, 1-129, or FL ␣syn (Fig. 11A) . Indeed, the pure C-truncated ␣syn fibrils resulted in little to no FL ␣syn aggregation, whereas FL ␣syn fibrils induced 18.3 Ϯ 5.3% aggregation (Fig. 11B) . These findings for seeding with FL and C-truncated ␣syn fibrils were confirmed by immunofluorescence analysis staining for ␣syn inclusion pathology using pSer 129 or 5G9 antibodies (Fig. 12) .
FL ␣syn fibrils potentiated and copolymerized with C-truncated ␣syn demonstrate robust activity as prion-like seeds in neuronal-glial culture
To investigate the potential for ␣syn fibrils composed of both FL and C-truncated ␣syn to induce pathology in neuronal cells, primary E16 neuronal-glial cultures were seeded with these mixed fibrils. 1-115, 1-125, or 1-129 ␣syn truncations were individually co-fibrillized with FL ␣syn and used to treat the neuronal cultures at 1.5 M for 10 days. Compared with fibrils composed solely of the C-truncated ␣syn proteins that induced little to no aggregation of the endogenous mouse ␣syn, the addition of the mixed fibrils led to an equal or even slightly greater amount of insoluble mouse ␣syn compared with FL ␣syn fibrils (Fig. 11) . These findings were confirmed by immunofluorescence analysis with anti-pSer 129 and 5G9 staining (Fig. 12) .
Discussion
In these studies, we systematically examined the aggregation properties of common and naturally occurring C-terminal truncations of ␣syn that were previously identified to form when either monomeric or fibrillar ␣syn are introduced to cells; most of these truncations have additionally been purified from LB inclusions in human disease (32, 34, (42) (43) (44) (45) (46) (47) (48) 82) . Our data suggest that the formation of these C-truncated species may contribute to initiating ␣syn aggregation. Mechanistically, the C terminus of ␣syn is seemingly engineered to inhibit aggregation due to several factors. First, the acidic residues in the C terminus promote a disordered structure and maintain protein solubility (83, 84) ; fusion of the C terminus to other proteins is even sufficient to render them solubilized and stable against heat-induced precipitation (85, 86) . Second, the C terminus has 
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autochaperoning abilities, whereby it establishes contacts with the hydrophobic NAC region to shield it from pathologic aggregation-inducing interactions (38, (87) (88) (89) (90) (91) . Lastly, the C terminus is the most proline-rich region in ␣syn, with 5 proline residues known to be unfavorable to ␤-sheet formation (83, 92) . Additionally, these C-terminal prolines form a Nedd4 ubiquitin ligase consensus sequence that promotes degradation of ␣syn (93) . All of these protective features are lost upon C-terminal truncation, and consequently C-terminal truncation of ␣syn has been repeatedly shown to promote in vitro fibril formation (35, 36, 38, (41) (42) (43) 94) . Comparatively, N-terminal truncation has been shown to either not affect aggregation or mildly decrease it (95) (96) (97) ; this is expected due to the inconsequential changes in basic biochemical properties, such as protein pI and hydrophobicity, that are induced when the amphipathic N terminus is truncated (Fig. S4) .
In vitro aggregation assays of these physiologic C-truncated forms of ␣syn demonstrated that C-terminal truncation enhances spontaneous fibril formation, with more extensive removal of residues generally corresponding to further acceleration of the polymerization process. Furthermore, for the 1-129 and shorter C-truncations there is an increase in the final extent of aggregation, suggesting that the critical concentration of monomers for fibril formation may be lower for the more extensive C-truncated species compared with FL ␣syn (17) . Analyzing polymers of C-truncated ␣syn using EM, the clearest morphologic difference between them and FL fibrils is a decrease in observed fibril length. In the context of nonseeded aggregation in which these fibrils were generated, this finding is likely because initial spontaneous aggregate formation for these C-truncated proteins occurred with high frequency, leading to an increased number of shorter fibrils as the monomer/fibril ratio decreased rapidly, not allowing individual fibrils to excessively elongate. Comparatively, the FL protein with a lesser propensity to spontaneously aggregate would be expected to have rarer fibril-forming events, allowing the initially formed fibrils to polymerize further before monomers are sufficiently depleted to halt fibrillization. This decrease in length with C-truncation has been noted previously in vitro for other forms of C-truncated ␣syn (35, 37, 38) , but never for these physiologic truncations. From these experiments, it is clear that physiologic C-truncation of ␣syn accelerates both the extent and rate of fibril formation, and the mechanism for this is likely due to a lower energy barrier for spontaneous initial aggregation, leading to the shorter fibrils observed in EM.
From initial cell culture experiments, it is evident that physiologic C-truncated ␣syn aggregates more extensively than FL ␣syn even in a cellular environment, but in the time frame of studies in HEK293T cells, this process requires seeding. Intriguingly, the truncations most similar to FL aggregate to a similar degree, but C-truncations that are 1-129 or shorter demonstrate a much greater amount of insoluble, aggregated ␣syn, which follows the trends in aggregation extent and speed determined in vitro. This accelerated aggregation seen when C-truncated forms of ␣syn are seeded with 21-140 ␣syn fibrils is presumably due to elongation of the initial seed fibrils from Pathologic C-terminal truncation of ␣-synuclein these monomers with more exposed NAC regions and less negative repulsion due to loss of acidic C-terminal residues. Cumulatively, the in vitro and cell culture experiments revealed that C-truncated ␣syn is primed to aggregate, which may be crucial in initial disease pathogenesis. Also, ␣syn fibrils are known to be trafficked to lysosomes in neurons (21, 98) , where these truncations are likely formed (22, 30 -34) , and may play a role in initial fibril-induced propagation of pathology, as the C-truncated forms of ␣syn are much more readily induced to aggregate compared with FL ␣syn.
Previous in vitro experiments have reported an enhancement of ␣syn aggregation when co-fibrillized with C-truncated ␣syn monomers (35, 42, 43) . Herein, we demonstrated that this phenomenon occurs with physiologic C-truncations of ␣syn and at low concentrations, close to physiologic 3 M (17), where FL ␣syn would otherwise not aggregate in vitro. It is demonstrated that co-incubation of FL ␣syn with 1-115 or 1-125 ␣syn increased not only the rate of FL ␣syn aggregation but also the final total extent, where nearly all of the FL ␣syn became insoluble under these conditions. These results demonstrate that C-truncated ␣syn may induce initial FL ␣syn fibril formation when it otherwise would not occur, and the mechanism for this appears to be mixed C-truncated/FL ␣syn fibril formation, as both FL and C-truncated forms of ␣syn became insoluble in equal proportions. The formation of the proposed mixed fibrils was shown by immuno-EM, where both C-truncated forms of ␣syn and 21-140 ␣syn were detected throughout fibrils when co-assembled. In cultured cells, co-transfection to express FL ␣syn with the more extensively C-truncated ␣syn species led to an almost doubling of FL ␣syn aggregation in the presence of 21-140 seed fibrils. Thus, C-truncated forms of ␣syn may be pathologically relevant not only due to their robust aggregation propensity and ability to be seeded by ␣syn fibrils, but also in synergistically accelerating seeded or unseeded aggregation of FL ␣syn. The cell culture results in the context of seeded aggregation could be explained by the aggregation-prone C-truncated monomers rapidly elongating the seed fibrils, promoting their eventual fracturing into smaller fibrils (containing both FL and C-truncated ␣syn) that are known to readily seed further templating (17, 19, 99, 100) . Our cumulative results suggest that aggregation-prone forms of C-truncated ␣syn may play a role in initial inclusion formation as they potentiate FL ␣syn aggregation through formation of mixed fibrils. Furthermore, the resulting mixed fibrils composed of both C-truncated and FL ␣syn demonstrated a potent ability to propagate further ␣syn aggregation in both HEK293T cells and primary neuronal-glial cultures. 
␣syn fibrils composed partially of C-truncated ␣syn along with FL ␣syn are probabilistically more likely to form than fibrils composed entirely of C-truncated ␣syn; however, the seeding ability of pure C-truncated ␣syn fibrils was investigated to understand the necessary role of the C terminus in fibril structure and pathogenicity. Indeed, these pure C-truncated ␣syn fibrils were less efficient in their induction of ␣syn aggregation, suggesting structural incompatibility between the seeds and endogenous ␣syn. These findings are consistent with previous in vitro findings and other reports in cultured cells, where 1-120 ␣syn fibrils or 1-99 ␣syn fibrils when added to cells also yield lower templating of FL ␣syn (41, 64, 66, 101, 102) . However, a study utilizing C-truncated fibrils formed from proteolytic digestion noted either equal or superior seeding compared with FL ␣syn fibrils (31), which is presumably due to mixed C-truncation/FL ␣syn fibril formation, as it is unlikely that all ␣syn within a fibril becomes C-truncated. The conflicting results of these previous studies are explained by our own observations, where any pathologic role of C-truncated ␣syn is likely mediated through synergistic aggregation with FL ␣syn and the appearance of mixed C-truncated/FL ␣syn fibrils but not through formation of only C-truncated fibrils. This notion agrees with a recent study where it was found that fibrils composed entirely of nonphysiologic C-truncated ␣syn may lead to structural incompatibility with FL ␣syn in cultured cells and in seeding of pathology in mouse models (102) .
In the context of prion-like conformational templating, it seems paradoxical that C-truncated ␣syn readily aggregates in the presence of FL ␣syn fibrils, but, conversely, the addition of pure C-truncated ␣syn fibrils to FL ␣syn leads to lessened fibril formation. All truncations used in this study have identical fibril core-forming residues from ϳ30 to 102, which includes the NAC region implicated in prion-like conformational templating (61, 63, (103) (104) (105) , suggesting that C-truncated ␣syn fibrils should still induce FL ␣syn fibril formation. These results might be explained by the recently discovered alternative structure assumed by fibrils composed entirely of C-truncated ␣syn (41) . In a typical ␣syn fibril, the highly charged and bulky disordered C termini must be maximally separated between ␣syn subunits, which is achieved with a less compact fibril structure. Comparatively, fibrils composed of C-truncated ␣syn can assume a more highly twisted and compact conformation that is not amenable to the addition of FL ␣syn, explaining the inefficient cross-seeding (41) . Under this model, C-truncated ␣syn would readily add onto FL fibrils; however, the addition of FL ␣syn to the more compact C-truncated fibrils would be less efficient, as unfavorable C-terminal repulsions would occur. This model is consistent with the data presented here and suggests that the C terminus and other common post-translational modifications may intrinsically alter fibril structure and resulting prion-like conformational templating. Differing proteolytic digestion profiles of C-truncated ␣syn fibrils corroborate the possibility that C-truncation has a profound effect on fibril structure that may lead to cross-seeding differences. Alterations in the ␣syn fibril ultrastructure may underlie prion-like strain differences and constitute C-truncated fibrils as alternative strains themselves.
In summary, these results suggest that physiologically C-truncated forms of ␣syn may be pathologic due to their strong aggregation propensity, their potentiation of FL ␣syn aggregation, and the ability of resulting mixed C-truncated/FL ␣syn fibrils to propagate further FL ␣syn aggregation. It is conceivable that the processing of ␣syn to form C-truncated ␣syn in lysosomes may facilitate initial ␣syn fibril formation through the mechanisms studied herein, resulting in fibrils capable of mediating the pathologic progression of LB pathology through subsequent prion-like spread. These experiments add to a growing collection of data supporting a lysosome-centered explanation of synucleinopathies, whereby pathologic impairment of proteostasis may be an important contributor to disease.
Experimental procedures
Antibodies
Anti-phosphorylated Ser 129 (pSer 129 ) ␣syn rabbit mAb EP1536Y was obtained from Abcam (Cambridge, MA). SNL-4 is a rabbit polyclonal antibody raised against residues 2-12 of ␣syn (72) . 4110 is a rabbit antibody raised against a peptide corresponding to residues 2-15 in human ␣syn with an added cysteine at the N terminus (CDVFMKGLSKAKEGV) for conjugation to maleimide-activated mariculture keyhold limpet hemocyanin (Thermo Scientific, Waltham, MA) as a service provided by GenScript (Piscataway, NJ). Antibody 4110 was further affinity-purified using recombinant FL human ␣syn conjugated to Affi-Gel 15 beads from Bio-Rad. 94-3A10 is a mouse mAb specific for the extreme C-terminal 130 -140 residues of ␣syn (80). 94-3A10 was further affinity-purified using a Protein G chromatography cartridge from Thermo Fisher Scientific. D37A6 is a rabbit mAb specific for mouse ␣syn that was purchased from Cell Signaling (Danvers, MA). The Tuj-1 mouse mAb for neuronal specific ␤III tubulin was purchased from R&D Systems (Minneapolis, MN). Neuronal specific rabbit anti-␤III tubulin antibody (T2200) was obtained from Sigma-Aldrich. Syn 506 is a mouse mAb to residues 2-12 of ␣syn that preferentially binds aggregated ␣syn (73, 106) .
Expression and purification of recombinant ␣syn proteins
Recombinant FL human ␣syn along with N-terminally truncated 21-140 human ␣syn were expressed from the pRK172 plasmid containing the cDNA for the SNCA gene as described previously (61, 67) . Additional stop codons were introduced in these two constructs through QuikChange site-directed mutagenesis (Agilent Technologies, Santa Clara, CA) using mutant-specific oligonucleotides to generate expression plasmids yielding eight different C-terminally truncated ␣syn proteins ( Fig. 1) (66) . All mutations and the absence of errors throughout the entire length of the ␣syn cDNA were confirmed by Sanger sequencing. FL (residues 1-140), 1-129, 1-133, 1-135, 21-140, 21-129, 21-133, and 21-135 ␣syn were expressed in Escherichia coli BL21 (DE3) and purified as described previously, utilizing size-exclusion and Mono Q anion-exchange chromatography (61) . For the shorter ␣syn truncations, which are 1- 115, 1-119, 1-122, 1-124, 1-125,  21-115, 21-119, 21-122, 21-124 , and 21-125 ␣syn, following expression in E. coli BL21 (DE3), proteins were purified with a Pathologic C-terminal truncation of ␣-synuclein modified procedure in which the Mono Q anion-exchange elution buffers were prepared at pH 9 to account for increasing pI in these truncated proteins. All recombinant proteins were diluted in pH 7.4 sterile PBS (Invitrogen), and concentrations were determined using the bicinchoninic acid assay (Pierce) with BSA as the standard.
In vitro aggregation of C-truncated ␣syn
For in vitro aggregation comparisons, FL and C-truncated ␣syn proteins were diluted to 150 M in sterile PBS (Invitrogen) and assembled into amyloid fibrils with continuous shaking at 1050 rpm, 37°C, for 0, 6, 12, 24, 48, 72 , and 96 h with four replicates per protein at each time point. Amyloid formation for each tube (n ϭ 4) was assessed by K114 and ThT fluorometry as described previously (60) . Additionally, insoluble polymer formation at the final time point (40 l of solution) was measured by centrifugation at 100,000 ϫ g for 30 min in PBS. SDS-sample buffer was added to the separated pellets and supernatants to the same final concentration (10 mM Tris, pH 6.8, 1 mM EDTA, 40 mM DTT, 0.005% bromphenol blue, 0.0025% pyronin yellow, 1% SDS, 10% sucrose). Supernatant and pellet samples at the same volume were boiled for 10 min, and equal volumes from each fraction were resolved in SDS-PAGE using 15% polyacrylamide gels. Gels were stained with Coomassie Blue R-250 to visualize protein and destained in 25% isopropyl alcohol, 10% acetic acid; densitometric analysis of stained ␣syn protein bands was conducted using the ImageJ program to quantify the fraction of insoluble ␣syn for each sample.
In vitro co-aggregation of C-truncated and FL ␣syn
To assay any enhancement of FL ␣syn aggregation when C-truncated ␣syn is present in vitro, 25 M FL ␣syn was mixed with a 25 M concentration of either the 1-115, 1-125, 1-129, or 1-135 ␣syn proteins and assembled into fibrils identically to the in vitro aggregation comparison experiment. At times of 0, 12, 24, 48, 72, and 96 h, 40 l of solution was withdrawn from each tube and analyzed through insolubility analysis as described for the in vitro aggregation comparison experiment. Densitometric analysis of the stained FL ␣syn protein band was conducted using the ImageJ program to quantify the percentage of FL ␣syn insoluble protein for each sample at each time point.
EM analysis of C-truncated ␣syn fibrils
␣syn fibrils prepared at 5 mg/ml underwent centrifugation at 100,000 ϫ g for 30 min, and the fibril-containing pellet was suspended in microscopy grade water. Centrifugation was repeated twice to remove salts from the pellet, after which fibrils were adsorbed onto 300-mesh carbon-coated copper grids (Electron Microscopy Sciences, Hatfield, PA), negatively stained with 1% uranyl acetate, and visualized with a Hitachi 7600 transmission electron microscope. Fibril widths for at least 100 fibrils per truncation were measured by a blinded observer using Image Pro-Plus software (Media Cybernetics).
To investigate the possibility of mixed fibril formation between C-truncated and FL ␣syn, fibrils were prepared at a total amount of 4 mg/ml but using 2 mg/ml human 21-140 ␣syn and 2 mg/ml either the 1-115 or 1-129 human C-truncated forms of ␣syn. A modified protocol for immunolabeling followed by EM was used (107) . Fibrils were washed as described above and similarly adsorbed onto grids. The grids were blocked with 2% serum BSA in PBS for 10 min and sequentially incubated with primary antibodies diluted in 2% BSA/ PBS; affinity-purified 4110 (20 g/ml; residues 2-15 of ␣syn) and 94-3A10 (20 g/ml; residues 130 -140) were used. Following washes with PBS, the grids were sequentially incubated with anti-mouse and anti-rabbit IgG secondary antibodies conjugated to 6 or 10 nm colloidal gold, respectively (Electron Microscopy Sciences, Hatfield, PA). Fibrils were negatively stained with 1% uranyl acetate and visualized with a Hitachi 7600 transmission electron microscope.
Proteolytic digestion of C-truncated ␣syn fibrils
FL and C-truncated ␣syn proteins were diluted to 5 mg/ml in sterile PBS (Invitrogen) and assembled into amyloid fibrils with continuous shaking at 1050 rpm and 37°C for 5 days. For proteolytic digestion, 40 g of each fibril was immediately diluted in sterile PBS to 1 mg/ml and incubated with either trypsin (Gibco) or proteinase K (Fisher) at two different concentrations for 30 min at 37°C. Concentrations of proteases relative to the amount of fibrils were similar to previous studies (64, 65) , with trypsin being used at 0.05 or 0.025 mg/ml and proteinase K being used at 0.005 or 0.0025 mg/ml. After 30 min, samples were placed on ice, and 1 mM phenylmethylsulfonyl fluoride was added to inhibit further digestion. SDS-sample buffer was added, and samples were heated to 100°C for 10 min and resolved on SDS-PAGE. Gels were stained with Coomassie Blue R-250 to visualize digestion products.
Preparation of ␣syn fibrils for seeding assays
For cell culture and animal experiments, FL or C-truncated ␣syn proteins were diluted to 5 mg/ml in sterile PBS (Invitrogen) and assembled into amyloid fibrils with continuous shaking at 1050 rpm, 37°C, for 5-7 days. Amyloid formation was confirmed by K114 and ThT fluorometry as described previously (60) . Fibrils were diluted to 2 mg/ml and fragmented by gentle bath sonication for 60 min prior to seeding experiments. For mixed C-truncation/21-140 fibrils used in HEK293T seeding, the 21-140 protein and one each of the doubly N-and C-truncated proteins were fibrillized together in a 1:1 ratio and a total concentration of 5 mg/ml. For mixed C-truncation/FL fibrils in primary culture seeding, fibrils were produced similarly but using C-truncated and FL human fibrils without the 1-20 truncation.
Mammalian expression plasmids
The cDNA encoding FL human ␣syn was previously cloned in the mammalian expression vector pcDNA3.1(ϩ) (66) . Plasmids encoding eight C-terminally truncated ␣syn constructs were generated using the same mutagenic oligonucleotides as for the pRK172 plasmid to introduce premature stop codons to ␣syn in the pcDNA3.1 plasmid. All mutations and the absence of errors throughout the entire length of the ␣syn cDNA were confirmed by Sanger sequencing.
Pathologic C-terminal truncation of ␣-synuclein
HEK293T cell culture and transfection HEK293T cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented to contain 2 mM L-glutamine, 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 g/ml streptomycin, at 37°C and 5% CO 2 . Cells were plated into 4-cm 2 wells and allowed to reach 30 -40% confluence, at which time cells were given fresh medium and transfected using a modified calcium phosphate protocol (66) . For one well containing 1 ml of medium, 1.5 g of pcDNA3.1 vector expressing either FL or C-truncated human ␣syn was diluted in 18.75 l of 0.25 M CaCl 2 , after which the mixture was added stepwise into an equal volume of 2ϫ BES buffer (50 mM N,N-bis(2-hydroxymethyl)-2-aminoethanesulfonic acid, 280 mM NaCl, 1.5 mM Na 2 HPO 4 , pH 6.96) to a final volume of 37.5 l. The DNA-containing solution was incubated at room temperature for 15 min prior to adding it dropwise to the well. For co-transfection studies, pcDNA3.1 plasmids were diluted in 0.25 M CaCl 2 in a 1:1 ratio for a total of 1.5 g of DNA/well. For seeding assays, preformed FL or C-truncated ␣syn fibrils were added to 1 M at 1 h after transfection, with the concentration being based on that of the monomeric subunits. At 16 h posttransfection, cells were washed with PBS, and medium was changed to Dulbecco's modified Eagle's medium culture medium containing 3% FBS. Cells were harvested for biochemical fractionation at a final time point of 64 h post-transfection. All sets of cell culture experiments for biochemical fractionation experiments were repeated at least one time.
HEK293T cell biochemical fractionation
HEK293T cells were washed once in PBS and subsequently lysed in 200 l/well detergent extraction buffer (25 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 20 mM NaF) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride and 1 mg/ml each of pepstatin, leupeptin, N-tosyl-L-phenylalanyl chloromethyl ketone, N-tosyllysine chloromethyl ketone, and soybean trypsin inhibitor). Detergent-insoluble material was sedimented at 100,000 ϫ g for 30 min at 4°C, and the supernatant was collected. To ensure complete removal of soluble material, centrifugation of the insoluble fraction was repeated before it was suspended in the same volume of detergent extraction buffer as the supernatant. Sample buffer was added to both fractions (10 mM Tris, pH 6.8, 1 mM EDTA, 40 mM DTT, 0.005% bromphenol blue, 0.0025% pyronin yellow, 1% SDS, 10% sucrose), and samples were boiled for 10 min. The insoluble fraction was additionally probe-sonicated for 1 min and boiled for an additional 10 min to ensure a homogenous solution prior to Western blot analysis.
Western blot analysis
Equal volumes of Triton-soluble and Triton-insoluble fractions were loaded onto 15% polyacrylamide gels and resolved by SDS-PAGE, followed by electrophoretic transfer onto 0.2-m pore size nitrocellulose membranes (Bio-Rad) in carbonate transfer buffer (10 mM NaHCO 3 , 3 mM Na 2 CO 3 , pH 9.9) (108). Membranes were blocked in 5% dry milk/Tris-buffered saline (TBS) and incubated overnight at 4°C with primary antibody diluted in block solution. For experiments where C-truncated fibrils were added, the 94-3A10 antibody (residues 130 -140) was utilized to avoid detection of exogenous fibrils. Similarly, the SNL-4 antibody (residues 2-12) was used when 21-140 fibrils or doubly N-and C-truncated fibrils were added, and mouse ␣syn-specific antibodies D37A6 or 5G9 were used when human fibrils were added to neuronal-glial cultures expressing mouse ␣syn. After washing in TBS, membranes were incubated in goat anti-rabbit or goat anti-mouse secondary antibodies conjugated to horseradish peroxidase (Jackson Immunoresearch Laboratories, Westgrove, PA) diluted in 5% dry milk/TBS for 1 h at room temperature; immunocomplexes were detected using Western LightningPlus ECL reagents (PerkinElmer Life Sciences) followed by chemiluminescence imaging (PXi, Syngene, Frederick, MD). Densitometry was performed using ImageJ software to quantify the ratio of detergent-insoluble to total ␣syn. Quantified aggregation amounts used only experiments performed at the same time to reduce variability, although results were confirmed in additional replicate experiments.
Immunofluorescence of HEK293T cells
For immunofluorescence analysis, HEK293T cells were plated onto poly-D-lysine-coated glass coverslips. Transfection was performed with pcDNA3.1 vector expressing either FL or C-truncated human ␣syn, and cells were subsequently treated with 1 M 21-140 ␣syn fibrils identically to biochemical fractionation experiments. 64 h after transfection, cells were rinsed with PBS and fixed with 4% paraformaldehyde for 10 min, followed by PBS washes. Cells were blocked with 5% FBS, PBS, 0.1% Triton X-100 for 30 min, followed by the application of primary antibodies Syn 506 and SNL4 diluted in block solution for 1 h at room temperature. Following PBS washes, fixed cells were then incubated with Alexa Fluor 488 -and 594 -conjugated secondary antibodies (Invitrogen) under the same conditions as for the primary antibody. Autofluorescence was quenched by application of 0.3% Sudan black for 10 min. Nuclei were counterstained with 4Ј,6-diamidino-2-phenylindole (DAPI; Invitrogen), and coverslips were mounted using Fluoromount-G (Southern Biotech, Birmingham, AL). Fluorescent images were captured using an Olympus BX51 fluorescence microscope mounted with a DP71 digital camera (Olympus, Center Valley, PA).
Mice
All animal experimental procedures were performed in adherence to University of Florida institutional animal care and use committee regulatory policies. Mice were housed under stable conditions with a 12-h light/dark cycle and access to food and water ad libitum. BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, MA), and C3HBL/6 mice were obtained from Charles River Laboratories (Wilmington, MA).
Production and validation of monoclonal antibodies selective for aggregated mouse ␣syn
A peptide containing residues 117-129 of mouse ␣syn along with an added N-terminal cysteine (CPVDPGSEAYEMPS) was synthesized by GenScript Inc. (Piscataway, NJ) and conjugated to mariculture keyhold limpet hemocyanin. Using this peptide, mice were immunized, followed by spleen harvest, hybridoma Pathologic C-terminal truncation of ␣-synuclein fusion, and screening for reactivity to mouse but not human ␣syn, as described previously (109) . The positive clones were next screened by Western blotting of 200 ng of recombinant mouse and human ␣syn or ϳ25 g of cell culture lysate from HEK293T cells expressing mouse or human ␣syn. Following validation of the antibodies for mouse ␣syn specificity, immunohistochemistry was used to screen for antibodies that preferentially bound mouse ␣syn in an aggregated state. Brains from C3HBL/6 mice known to contain pathologic inclusions after intrastriatal injection of mouse ␣syn fibrils (81) were stained using hybridoma medium, as a number of these mice contain pathologic inclusions composed of mouse ␣syn in the ipsilateral but not contralateral entorhinal cortex. Sections were observed for preferential staining of inclusions with low background staining of physiologic mouse ␣syn. Tissue processing and sectioning as well as immunohistochemical antigen retrieval and staining were performed as described previously (110) .
Primary neuronal-glial culture preparation
E16 -18 C3HBL/6 mice were used to prepare primary mixed neuronal-glial cultures from cerebral cortices and maintained for 16 days total, as described previously (21) . Cells were plated onto Nunc Lab-Tek II CC2 chamber slides (for immunofluorescence) or poly-D-lysine-coated 9-cm 2 wells (for biochemistry) at ϳ100,000 -200,000 cells/cm 2 . Cultures prepared using this method are usually 20% neuronal and 80% glial in composition (21) . Cultures were maintained at 37°C, 5% CO 2 in Neurobasal-A medium (Gibco) supplemented with 1% GlutaMax (Life Technologies), B-27, 100 units/ml penicillin, and 100 g/ml streptomycin, with half the medium removed to fresh medium at day 2 and then every 4 days thereafter. Additionally, the initial plating medium contained 1% FBS.
Primary neuronal-glial culture seeding and aggregation assays
To study seeded aggregation in primary neuronal-glial cultures, preformed FL or C-truncated ␣syn fibrils were used similarly to the HEK293T experiments. At culture day 6 following fresh medium change, recombinant ␣syn fibrils were added to a final concentration of 1.5 M, with the concentration being based on that of the monomeric subunits. Cells were then maintained for 10 more days and subsequently harvested for biochemical or immunofluorescence assays. Biochemical fractionation and Western blot analysis were performed as described for HEK293T cells. For double immunofluorescence analysis, cells were washed with PBS followed by fixation with 4% paraformaldehyde in PBS. Cells were subsequently blocked with 5% FBS, PBS, 0.1% Triton X-100 and then incubated for 1 h at room temperature with primary antibodies prepared in the block solution. Primary antibodies used for these experiments were the Tuj-1 or T2200 antibody for neuronal-specific ␤III tubulin combined with either EP1536Y for pSer 129 or 5G9 against aggregated mouse ␣syn. Following PBS washes, fixed cells were then incubated with Alexa Fluor 488 -and 594 -conjugated secondary antibodies (Invitrogen) under the same conditions as for the primary antibody. Nuclei were counterstained with DAPI (Invitrogen), and coverslips were mounted using Fluoromount-G (Southern Biotech). Fluorescent images were captured using an Olympus BX51 fluorescence microscope mounted with a DP71 digital camera (Olympus).
Quantitative analysis
Western blotting and SDS-PAGE data for aggregation comparison were quantified by ImageJ software (National Institutes of Health, Bethesda, MD). The insoluble ␣syn fraction was reported as the ratio of the intensity of the ␣syn band in the insoluble fraction divided by the summed intensities of ␣syn in the soluble and insoluble fractions. Densitometric comparisons were performed in GraphPad Prism software using either oneway or two-way analysis of variance (ANOVA), with post hoc analysis using Dunnett's test to compare each truncation with the FL control.
For fluorometry data, spectroscopic readings for each replicate sample were blank-subtracted and averaged before using two-way ANOVA, with post hoc analysis using Dunnett's test to compare the normalized fluorescence of each truncation at each time point with the FL control.
